^
Association details:
| Biomarker: | HR positive + BRCA1 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
Published date:
07/20/2023
Excerpt:
Tissue was collected from 89 patients with HR+/HER2- MBC, including those with recurrent and/or metastatic disease, receiving palbociclib plus an aromatase inhibitor or fulvestrant...Likewise, the presence of mutated BRCA1/2 was associated with shorter PFS (HR = 2.67; p = 0.012, q = 0.049). Mutation of TP53 (HR = 3.92; p < 0.001, q < 0.001) and APOBEC signature S13 (HR = 3.19; p = 0.002, q = 0.012) were associated with shorter PFS.
Secondary therapy:
Aromatase inhibitor; fulvestrant
DOI:
https://doi.org/10.1186/s13073-023-01201-7
